RecruitingNCT06919341
RESTI Registry: Spanish Registry of Primary Immune Thrombocytopenia and Other Immune Thrombocytopenia
Studying Autoimmune thrombocytopenia
Last synced from ClinicalTrials.gov
ℹ
Clinical trial records are synced from ClinicalTrials.gov through automated extraction.
Report missing dataKey facts
- Sponsor
- Fundación Española de Hematología y Hemoterapía
- Enrollment
- 1000 enrolled
- Eligibility
- All sexes
- Timeline
- 2024 – 2034
Study locations (30)
- Complexo Hospitalario Universitario A Coruña, A Coruña, A Coruña, Spain
- Hospital Universitario Son Espases, Palma, Balearic Islands, Spain
- Hospital Del Mar, Barcelona, Barcelona, Spain
- Hospital Vall d'Hebron (, Barcelona, Barcelona, Spain
- Hospital Universitario Mutua Terrassa, Terrassa, Barcelona, Spain
- Hospital de Basurto, Bilbao, Biskaia, Spain
- Hospital Sierrallana, Torrelavega, Cantabria, Spain
- Hospital de La Plana, Castellon, Castellón, Spain
- Hospital Universitario Punta de Europa, Algeciras, Cádiz, Spain
- Hospital Puerta del Mar, Cadiz, Cádiz, Spain
- Hospital Universitario de Jerez, Jerez de la Frontera, Cádiz, Spain
- Hospital Universitario Reina Sofia de Córdoba, Córdoba, Córdoba, Spain
- Hospital Universitario Virgen de las Nieves, Granada, Granada, Spain
- Hospital Juan Ramón Jimenez, Huelva, Huelva, Spain
- Complejo Hospitalario de Jaén, Jaén, Jaén, Spain
- +15 more locations on ClinicalTrials.gov
Primary source
Recruitment status, site addresses, contacts, and full eligibility criteria can change between syncs. Always verify with the trial team before planning travel or treatment.
Open NCT06919341 on ClinicalTrials.govOther trials for Autoimmune thrombocytopenia
Additional recruiting or active studies for the same condition.
- RECRUITINGPHASE3NCT07559331High-Dose Dexamethasone Combined With Orelabrutinib Versus High-Dose Dexamethasone Combined With Placebo in Adult Patients With Newly Diagnosed Primary Immune ThrombocytopeniaShandong University
- RECRUITINGPHASE2NCT07362199Anti-CD38 Monoclonal Antibody Combined With Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)Institute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE2NCT07362238Daratumumab Versus Rituximab in the Management of Pediatric Primary Immune Thrombocytopenia (ITP)Institute of Hematology & Blood Diseases Hospital, China
- RECRUITINGEARLY PHASE1NCT07441525UCAR-T Targeting CD19/BCMA in Subjects With Autoantibody-Mediated Autoimmune Benign Hematological DiseasesUnion Hospital, Tongji Medical College, Huazhong University of Science and Technology
- RECRUITINGPHASE2NCT07234019Rituximab Combining Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)Institute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE2NCT07297563Anti-CD38 Monoclonal Antibody Versus Rituximab in the Management of Primary Immune Thrombocytopenia (ITP)Institute of Hematology & Blood Diseases Hospital, China
- RECRUITINGPHASE2NCT07294365A Study of DZD8586 in Adults With Primary Immune Thrombocytopenia (ITP) (TAI-SHAN11)Dizal Pharmaceuticals
- RECRUITINGPHASE2NCT07104565Study to Assess the Safety and Tolerability of Tafasitamab in Adult Participants With Primary Autoimmune Blood Cell DisordersIncyte Corporation